New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: A budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Restelli, Umberto ^a,b   Scolari, Francesca ^a   Bonfanti, Paolo ^c   Croce, Davide ^a,b   Rizzardini, Giuliano ^d,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c A MANZONI HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; GENERIC DRUG; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NEW DRUG; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL;

ARTICLE; BUDGET; COST CONTROL; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; SENSITIVITY ANALYSIS; SIMULATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PUBLIC HEALTH; RESOURCE ALLOCATION; SUPPLY AND DISTRIBUTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; HIV INFECTIONS; HUMANS; ITALY; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; RESOURCE ALLOCATION;

EID: 84938776025     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1077-7     Document Type: Article

References (23)

1. Helleberg M, Häggblom A, Sönnerborg A, Obel N. HIV care in the Swedish-Danish HIV cohort 1995 - 2010, closing the gaps. PLoS One. 2013;8(8), e72257.
2. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990 - 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005-70.
3. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-33.
4. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov. 2007;6(12):959-66.
5. Health Care Technology Institute. Decomposition of the Health Care spending residual. Alexandria, VA; 1994.
6. Christensen CM, Bohmer R, Kenagy J. Will disruptive innovations cure health care? Harv Bus Rev. 2000;78(5):102-12.
7. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med. 2005;142:932-7.
8. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-80.
9. Magoni M, Scarcella C, Vassallo F, Lonati F, Carosi G, Castelnuovo F, et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011;12(3):129-37.
10. Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Casartelli L, et al. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr. 2011;57(3):211-7.
11. Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, et al. Cost of human immunodeficiency virus infection in Italy, 2007 - 2009: effective and expensive, are the new drugs worthwhile? Clinicoecon Outcomes Res. 2012;4:245-52.
12. Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S, Stuckler D, et al. Financial crisis, austerity, and health in Europe. Lancet. 2013;381(9874):1323-31.
13. Ruckert A, Labonté R. The global financial crisis and health equity: early experiences from Canada. Global Health. 2014;10:2.
14. Raffi F, Reynes J. Antiretroviral treatment French guidelines 2013: economics influencing science. J Antimicrob Chemother. 2014;69(5):1158-61.
15. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5-14.
16. Italian National Institute of Health, AIDS Operative Centre. Notiziario dell'Istituto Superiore di Sanità. 2013;26(7 - 8). http://www.iss.it/binary/publ/cont/Notiziario_ISS_luglio__Ago2013.pdf Accessed 3 August 2015
17. Directorate General for Health of Lombardy Region D.d.g. 22 December 2014 - n. 12515 - Approvazione del documento avente ad oggetto "Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS - anno 2105. http://omceomi.it/docs/default-source/leggi-e-norme/percorso-diagnostico-terapeutico-paziente-affetto-da-malattia-hiv-aids-anno-2015-burl-30-12-2014.pdf?sfvrsn=0. Accessed 15 May 2015.
18. Directorate General for Health of Lombardy Region D.d.g. 1 March 2013 - n. 1725 - Approvazione del documento avente ad oggetto "Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS. http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=4300. Accessed 15 Sep 2014.
19. Directorate General for Health of Lombardy Region D.d.g. 17 March 2014 - n. 2265 - Approvazione del documento avente ad oggetto "Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS - anno 2014". http://www.sanita.regione.lombardia.it/shared/ccurl/465/359/DDG2014_2265_pdt_hiv.pdf. Accessed 15 May 2015.
20. Italian Medicines Agency, The Medicines Utilization Monitoring Centre, Drug Utilisation Monitoring Centre report 2012; Rome, 2013. http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf. Accessed 15 Sep 2014.
21. Italian National Institute of Health, AIDS Operative Centre. Notiziario dell'Istituto Superiore di Sanità. 2013;26(9 Suppl1). http://www.iss.it/binary/publ/cont/coa2013.pdf Accessed 3 August 2015
22. Angeletti C, Pezzotti P, Antinori A, Mammone A, Navarra A, Orchi N, et al. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Med. 2014;15(3):165-74.
23. Hill A, Hill T, Jose S, Pozniak A. Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014 - 2018. J Int AIDS Soc. 2014;17(4 Suppl 3):19497.